Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
Identifieur interne : 000413 ( PubMed/Checkpoint ); précédent : 000412; suivant : 000414Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
Auteurs : C. Lacroix [France] ; J L Tranvouez ; T. Phan Hoang ; H. Duwoos ; O. LafontSource :
- Arzneimittel-Forschung [ 0004-4172 ] ; 1990.
English descriptors
- KwdEn :
- MESH :
- chemical , analogs & derivatives : Pyrazinamide.
- chemical , blood : Pyrazinamide.
- metabolism : Liver Cirrhosis, Pyrazinamide.
- chemical , pharmacokinetics : Pyrazinamide.
- Adult, Chromatography, High Pressure Liquid, Female, Half-Life, Humans, Liver Function Tests, Male.
Abstract
The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared to those of a group of nine healthy subjects (control group). The results exhibit a marked reduction of the pyrazinamide total clearance (0.48 vs 0.84 ml.min-1.kg-1) and an increase in half-life from 9.19 h to 15.07 h in the patients group. The area under the curve of pyrazinoic acid (the main metabolite) is increased from 97 to 280 mg.h.l-1 with a half-life twice as much as that of the control group. The hepatic insufficiency entails a marked reduction of the common posology as well as a closer survey of the biologic hepatic parameters and of uric acid the renal elimination of which is inhibited by pyrazinoic acid.
PubMed: 2340003
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:2340003Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.</title>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
<affiliation wicri:level="1"><nlm:affiliation>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre</wicri:regionArea>
<placeName><settlement type="city">Le Havre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tranvouez, J L" sort="Tranvouez, J L" uniqKey="Tranvouez J" first="J L" last="Tranvouez">J L Tranvouez</name>
</author>
<author><name sortKey="Phan Hoang, T" sort="Phan Hoang, T" uniqKey="Phan Hoang T" first="T" last="Phan Hoang">T. Phan Hoang</name>
</author>
<author><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name>
</author>
<author><name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:2340003</idno>
<idno type="pmid">2340003</idno>
<idno type="wicri:Area/PubMed/Corpus">000441</idno>
<idno type="wicri:Area/PubMed/Curation">000441</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000441</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.</title>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
<affiliation wicri:level="1"><nlm:affiliation>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre</wicri:regionArea>
<placeName><settlement type="city">Le Havre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tranvouez, J L" sort="Tranvouez, J L" uniqKey="Tranvouez J" first="J L" last="Tranvouez">J L Tranvouez</name>
</author>
<author><name sortKey="Phan Hoang, T" sort="Phan Hoang, T" uniqKey="Phan Hoang T" first="T" last="Phan Hoang">T. Phan Hoang</name>
</author>
<author><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name>
</author>
<author><name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name>
</author>
</analytic>
<series><title level="j">Arzneimittel-Forschung</title>
<idno type="ISSN">0004-4172</idno>
<imprint><date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Female</term>
<term>Half-Life</term>
<term>Humans</term>
<term>Liver Cirrhosis (metabolism)</term>
<term>Liver Function Tests</term>
<term>Male</term>
<term>Pyrazinamide (analogs & derivatives)</term>
<term>Pyrazinamide (blood)</term>
<term>Pyrazinamide (metabolism)</term>
<term>Pyrazinamide (pharmacokinetics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Liver Cirrhosis</term>
<term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Female</term>
<term>Half-Life</term>
<term>Humans</term>
<term>Liver Function Tests</term>
<term>Male</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared to those of a group of nine healthy subjects (control group). The results exhibit a marked reduction of the pyrazinamide total clearance (0.48 vs 0.84 ml.min-1.kg-1) and an increase in half-life from 9.19 h to 15.07 h in the patients group. The area under the curve of pyrazinoic acid (the main metabolite) is increased from 97 to 280 mg.h.l-1 with a half-life twice as much as that of the control group. The hepatic insufficiency entails a marked reduction of the common posology as well as a closer survey of the biologic hepatic parameters and of uric acid the renal elimination of which is inhibited by pyrazinoic acid.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2340003</PMID>
<DateCreated><Year>1990</Year>
<Month>6</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted><Year>1990</Year>
<Month>06</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-4172</ISSN>
<JournalIssue CitedMedium="Print"><Volume>40</Volume>
<Issue>1</Issue>
<PubDate><Year>1990</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Arzneimittel-Forschung</Title>
<ISOAbbreviation>Arzneimittelforschung</ISOAbbreviation>
</Journal>
<ArticleTitle>Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.</ArticleTitle>
<Pagination><MedlinePgn>76-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared to those of a group of nine healthy subjects (control group). The results exhibit a marked reduction of the pyrazinamide total clearance (0.48 vs 0.84 ml.min-1.kg-1) and an increase in half-life from 9.19 h to 15.07 h in the patients group. The area under the curve of pyrazinoic acid (the main metabolite) is increased from 97 to 280 mg.h.l-1 with a half-life twice as much as that of the control group. The hepatic insufficiency entails a marked reduction of the common posology as well as a closer survey of the biologic hepatic parameters and of uric acid the renal elimination of which is inhibited by pyrazinoic acid.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacroix</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tranvouez</LastName>
<ForeName>J L</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Phan Hoang</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Duwoos</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lafont</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
</AuthorList>
<Language>ENG</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Arzneimittelforschung</MedlineTA>
<NlmUniqueID>0372660</NlmUniqueID>
<ISSNLinking>0004-4172</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>13924-96-4</RegistryNumber>
<NameOfSubstance UI="C032191">5-hydroxypyrazinamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2KNI5N06TI</RegistryNumber>
<NameOfSubstance UI="D011718">Pyrazinamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2WB23298SP</RegistryNumber>
<NameOfSubstance UI="C005296">pyrazinoic acid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>34604-60-9</RegistryNumber>
<NameOfSubstance UI="C054996">5-hydroxypyrazinoic acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008111" MajorTopicYN="N">Liver Function Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011718" MajorTopicYN="N">Pyrazinamide</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1990</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1990</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">2340003</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<settlement><li>Le Havre</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name>
<name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name>
<name sortKey="Phan Hoang, T" sort="Phan Hoang, T" uniqKey="Phan Hoang T" first="T" last="Phan Hoang">T. Phan Hoang</name>
<name sortKey="Tranvouez, J L" sort="Tranvouez, J L" uniqKey="Tranvouez J" first="J L" last="Tranvouez">J L Tranvouez</name>
</noCountry>
<country name="France"><noRegion><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000413 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000413 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/France |area= LeHavreV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:2340003 |texte= Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:2340003" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LeHavreV1
This area was generated with Dilib version V0.6.25. |